ZYCOS Presents VIVACE(TM) Gene-Based Drug Development Program at IBC Target Validation Conference

Apr 18, 2001, 01:00 ET from ZYCOS Inc.

    LEXINGTON, Mass., April 18 /PRNewswire Interactive News Release/ -- ZYCOS
 Inc., a privately held biotechnology company, today announced that it will
 give a presentation on its VIVACE(TM) gene-based drug development program at
 the IBC 2nd Annual International Conference on Target Validation, Applying
 Effective Technologies to Accelerate Early Discovery, to be held April 23rd-
 25th at the Paradise Point Resort in San Diego, California.  The Company will
 also be hosting an exhibit booth featuring ZYCOS' platform technologies.
     Dr. Robert G. Urban, Vice President of New Technologies and Targets and a
 co-founder of ZYCOS Inc. will present on Wednesday, April 25th.
     The VIVACE program is able to take validated gene targets to the clinic in
 12-18 months.  VIVACE streamlines drug development by consistently using
 ZYCOS' plasmid DNA vector technologies and microsphere DNA delivery system for
 validation of gene targets, preclinical testing and human clinical drugs.  The
 manufacturing component of VIVACE is currently scaled to accommodate Phase III
 clinical trials.
     Using its technology platform, ZYCOS is building a pipeline of proprietary
 drugs.  ZYCOS can also offer VIVACE to pharmaceutical and genomic companies
 who have libraries of proprietary genes and are interested in rapidly turning
 them into products.
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts.  ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease.  ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens.  The company has also developed novel systems for
 DNA expression and DNA drug delivery.  ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     CONTACTS:
     Melissa Chen                             Sharon Weinstein
     Director of Business Development         Noonan/Russo Communications
     781-274-6500, ext. 211                   212-696-4455, ext. 227
     mchen@zycos.com                          s.weinstein@noonanrusso.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X85677252
 
 

SOURCE ZYCOS Inc.
    LEXINGTON, Mass., April 18 /PRNewswire Interactive News Release/ -- ZYCOS
 Inc., a privately held biotechnology company, today announced that it will
 give a presentation on its VIVACE(TM) gene-based drug development program at
 the IBC 2nd Annual International Conference on Target Validation, Applying
 Effective Technologies to Accelerate Early Discovery, to be held April 23rd-
 25th at the Paradise Point Resort in San Diego, California.  The Company will
 also be hosting an exhibit booth featuring ZYCOS' platform technologies.
     Dr. Robert G. Urban, Vice President of New Technologies and Targets and a
 co-founder of ZYCOS Inc. will present on Wednesday, April 25th.
     The VIVACE program is able to take validated gene targets to the clinic in
 12-18 months.  VIVACE streamlines drug development by consistently using
 ZYCOS' plasmid DNA vector technologies and microsphere DNA delivery system for
 validation of gene targets, preclinical testing and human clinical drugs.  The
 manufacturing component of VIVACE is currently scaled to accommodate Phase III
 clinical trials.
     Using its technology platform, ZYCOS is building a pipeline of proprietary
 drugs.  ZYCOS can also offer VIVACE to pharmaceutical and genomic companies
 who have libraries of proprietary genes and are interested in rapidly turning
 them into products.
     ZYCOS (http://www.zycos.com) is a privately held company located in
 Lexington, Massachusetts.  ZYCOS' core technology platform has led to the
 development of a new category of therapeutic medicines targeting multi-billion
 dollar markets in the areas of cancer, viral infections and autoimmune
 disease.  ZYCOS' discovery technology enables the rapid discovery of
 disease-specific antigens.  The company has also developed novel systems for
 DNA expression and DNA drug delivery.  ZYCOS' first product candidate, ZYC101a
 is designed to treat cervical infections associated with the human
 papillomavirus and is currently in Phase II clinical studies.
 
     CONTACTS:
     Melissa Chen                             Sharon Weinstein
     Director of Business Development         Noonan/Russo Communications
     781-274-6500, ext. 211                   212-696-4455, ext. 227
     mchen@zycos.com                          s.weinstein@noonanrusso.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X85677252
 
 SOURCE  ZYCOS Inc.